气球肺血管整形术后肺动脉平均压的临床影响
Ryo Takano1,2, Aoki Tatsuo1, Shinya Fujisaki1,2
1Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
慢性血栓塞性肺高血压 (CTEPH) 的气球肺血管整形术 (BPA) 在较低的平均肺动脉压 (mPAP) 显示出更好的结果. 达到≤20mmHg的mPAP与改善功能和减少治疗需求有关,这表明个性化目标.
科学领域:
- 心脏病学
- 肺病学
- 干预心脏病学
背景情况:
- 气球肺血管整形 (BPA) 是一种治疗无法手术的慢性血栓塞性肺高血压 (CTEPH) 的方法.
- 之前的BPA治疗目标是平均肺动脉压 (mPAP) 低于30 mm Hg.
- 在BPA后的mPAP水平对患者的临床意义尚未完全理解.
研究的目的:
- 根据BPA后的mPAP进行分层.
- 评估BPA后mPAP水平与临床状况之间的关联.
- 评估BPA后mPAP对长期结果的影响.
主要方法:
- 对304名接受BPA治疗的无法手术的CTEPH患者进行了回顾.
- 随访右心腔导管测量mPAP.
- 根据BPA后的mPAP,将患者分为三个组:≤20 mm Hg,>20-<30 mm Hg和≥30 mm Hg.
主要成果:
- 较低的mPAP水平与更好的世卫组织功能分类,6分钟的步行距离和右心室喷射分数相关.
- 患有较低mPAP的患者需要较少的肺血管扩张剂和氧气治疗.
- 与≤20mmHg的mPAP相比,≥30mmHg的mPAP与更差的预后相关;mPAP≤20和>20-<30mmHg组之间没有发现显著差异.
结论:
- 在BPA后的mPAP低于30mmHg与CTEPH患者的预后有关.
- 达到≤20mmHg的mPAP与更好的症状控制,运动能力和右心室功能有关.
- 在BPA治疗后,mPAP的最佳治疗目标可能需要针对每个患者进行个性化.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


